BMJ  2007;335:223 (4 August), doi:10.1136/bmj.39294.547326.DB

News

Diabetes study shows nothing new, says journal editor

Janice Hopkins Tanne

New York

The first 150 words of the full text of this article appear below.

Vivian Fonseca, the editor of Diabetes Care, told the BMJ that he was surprised by the media's interest in a study that says that rosiglitazone (Avandia) and pioglitazone (Actos) doubled the risk of heart failure in patients with type 2 diabetes (Diabetes Care 2007;30:2148-53 doi: 10.2337/dc07-0141).

The authors said that although drugs in the thiazolidinedione class were known to increase the risk of heart failure in patients with type 2 diabetes, the magnitude of the risk had not been evaluated. They used teleoanalysis to look at results from many different types of trials, involving 78 000 patients, and concluded that one in every 50 patients with type 2 diabetes taking one of these drugs would develop heart failure in a period of 26 months and need admission to hospital (see BMJ 2003;327:616-8 doi: 10.1136/bmj.327.7415.616 for an explanation of teleoanalysis).

Heart failure occurred at low and high doses . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Articles

FDA committees say keep rosiglitazone available but increase warnings
Janice Hopkins Tanne
BMJ 2007 335: 223. [Extract] [Full Text] [PDF]

Teleoanalysis: combining data from different types of study
Nicholas J Wald and Joan K Morris
BMJ 2003 327: 616-618. [Extract] [Full Text] [PDF]

Access jobs at BMJ Careers
Whats new online at Student BMJ